Connect with us

Business

Earnings Miss For Eli Lilly, But Guidance For The Full Year Is Raised

Published

on

Earnings Miss For Eli Lilly, But Guidance For The Full Year Is Raised

(CTN News) – Eli Lilly missed expectations when reporting first-quarter earnings. However, the company raised its full-year guidance.

This is in addition to the positive data the company reported on its weight loss drug tirzepatide just prior to the earnings release.

During the pre-market hours, Eli Lilly shares rose more than 3%.

Due to a reduction in sales of its Covid-19 antibodies by $1.5 billion, the company’s revenue dropped 11% compared to the same quarter last year, as a result of a decline in sales of $1 billion.

A report published by Lilly showed that the company’s revenue for the quarter rose to $6.96 billion, a slight increase over analysts’ expectations, but a decline from $7.81 billion in the same period last year.

There was an adjusted earnings per share of $1.62 for the quarter, which fell short of analyst expectations for $1.73 a share for the period.

Compared with the analysts’ estimates compiled by Refinitiv, here’s how the company did compared with what the company was expected to do:

  • The adjusted earnings per share were $1.62, compared to the $1.73 per share expected by the market

  • Compared with $6.86 billion expected, revenue came in at $6.96 billion

As of the first quarter of 2022, the company reported a net income of $1.3 billion or $1.49 per share, which is a decrease of 29% compared to the company’s first quarter of 2021, which was $1.5 billion.

Eli Lilly raised its guidance for the year as a result of a large part of the U.S. dollar’s weakness in comparison with other major currencies over the past year.

According to the company, revenues are expected to be between $31.2 billion and $31.7 billion, which is compared to its previous projections of $30.3 billion to $30.8 billion.

As a result, the company has increased its adjusted earnings guidance for the year to $8.65 to $8.85 per share, up from $8.35 to $8.55 per share previously.

The results of Lilly’s weight loss drug tirzepatide were also released Thursday morning before the company’s earnings release.

On average, patients with obesity and type 2 diabetes lost between 30 pounds and 34 pounds according to the dose they took, compared to the placebo group who lost 7 pounds on average.

It is expected that Lilly will finalize its application for approval by the Food and Drug Administration within the next few weeks.

SEE ALSO:

Layoffs At Amazon: Read The Memos Announcing The Cuts

Salman Ahmad is a seasoned writer for CTN News, bringing a wealth of experience and expertise to the platform. With a knack for concise yet impactful storytelling, he crafts articles that captivate readers and provide valuable insights. Ahmad's writing style strikes a balance between casual and professional, making complex topics accessible without compromising depth.

Continue Reading